Literature DB >> 8845249

CT and MR imaging of the liver using liver-specific contrast media. A comparative study in a tumour model.

P Leander1, S Månsson, T Ege, J Besjakov.   

Abstract

PURPOSE: A new type of liposomal liver-specific contrast medium (CM) in CT was studied, and the results were compared with those obtained with Mn-DPDP, a paramagnetic hepatobiliary CM, in MR imaging. The contrasts of normal liver tissue to tumorous tissue and the importance of the CM for tumour detection in the 2 modalities were studied in a rabbit tumour model. CT and T1-weighted pre- and postcontrast and T2-weighted MR images precontrast were obtained. MATERIAL, METHODS AND
RESULTS: Compared to precontrast images, significantly higher contrasts of normal liver tissue to tumorous tissue were obtained after CM administration in both CT and MR examinations. At radiologic evaluation, significantly more tumours were detected after CM administration in CT and in T1-weighted MR images than in precontrast images in CT and T1-weighted MR. There were no significant differences in tumour detection frequency in MR studies including a T2-weighted pulse sequence, postcontrast CT, or postcontrast T1-weighted MR imaging.
CONCLUSION: The use of liver-specific CM improves visualization of liver tumours in CT and T1-weighted MR imaging.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8845249     DOI: 10.1177/02841851960371P155

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  2 in total

1.  Non-invasive imaging of barriers to drug delivery in tumors.

Authors:  Yaron Hassid; Erez Eyal; Raanan Margalit; Edna Furman-Haran; Hadassa Degani
Journal:  Microvasc Res       Date:  2008-06-27       Impact factor: 3.514

2.  Establishment and evaluation of the VX2 orthotopic lung cancer rabbit model: a ultra-minimal invasive percutaneous puncture inoculation method.

Authors:  Lijuan Wang; Keke Che; Zhonghong Liu; Xianlong Huang; Shifeng Xiang; Fei Zhu; Yu Yu
Journal:  Korean J Physiol Pharmacol       Date:  2018-04-25       Impact factor: 2.016

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.